摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5-氯-2-(三氟甲基)苯基)硼酸 | 1195945-67-5

中文名称
(5-氯-2-(三氟甲基)苯基)硼酸
中文别名
5-氯-2-(三氟甲基)苯硼酸
英文名称
5-chloro-2-trifluoromethylphenylboronic acid
英文别名
5-Chloro-2-(trifluoromethyl)phenylboronic acid;[5-chloro-2-(trifluoromethyl)phenyl]boronic acid
(5-氯-2-(三氟甲基)苯基)硼酸化学式
CAS
1195945-67-5
化学式
C7H5BClF3O2
mdl
——
分子量
224.375
InChiKey
ILPIBSAMAZDGRC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    313.7±52.0 °C(Predicted)
  • 密度:
    1.49±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.04
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    40.5
  • 氢给体数:
    2
  • 氢受体数:
    5

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2931900090
  • 危险类别:
    IRRITANT
  • 危险性防范说明:
    P261,P280,P301+P312,P302+P352,P305+P351+P338
  • 危险性描述:
    H302,H315,H320,H335

反应信息

  • 作为反应物:
    描述:
    (5-氯-2-(三氟甲基)苯基)硼酸 在 dichloro[1,1'-bis(di-t-butylphosphino)ferrocene]palladium(II) 、 potassium carbonate 、 lithium hydroxide 作用下, 以 四氢呋喃1,4-二氧六环 为溶剂, 反应 7.0h, 生成 4-(5-chloro-2-(trifluoromethyl)phenyl)-6-methylpyridine-3-carboxylic acid
    参考文献:
    名称:
    [EN] SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF
    [FR] COMPOSÉ CYCLOTHIAZOLE À SIX CHAÎNONS ET SON UTILISATION
    [ZH] 六元环并噻唑类化合物及其应用
    摘要:
    本公开提供了一种式(I)所示的六元环并噻唑类化合物或其药学上可接受的盐,含有它们的药物组合物以及它们在预防或治疗DNA聚合酶θ介导的疾病中的应用。
    公开号:
    WO2023134739A1
点击查看最新优质反应信息

文献信息

  • Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20160052884A1
    公开(公告)日:2016-02-25
    The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    这项发明涉及替代的氧代吡啶衍生物及其制备方法,以及它们用于制备用于治疗和/或预防疾病的药物,特别是心血管疾病,优选是血栓性或血栓栓塞性疾病、水肿以及眼科疾病。
  • 치환된 옥소피리딘 유도체 및 심혈관 장애의 치료에서의 그의 용도
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT 바이엘 파마 악티엔게젤샤프트(519980697332)
    公开号:KR20150137095A
    公开(公告)日:2015-12-08
    본 발명은 하기 화학식 I의 치환된 옥소피리딘 유도체, 및 그의 제조 방법 및 질환, 특히 심혈관 질환, 바람직하게는 혈전성 또는 혈전색전성 질환, 및 부종, 및 또한 안과 장애의 치료 및/또는 예방을 위한 의약의 제조를 위한 그의 용도에 관한 것이다. <화학식 I> 상기 식에서, R1은 하기 화학식의 기이고, 여기서 *는 옥소피리딘 고리에 대한 부착 부위이고, R6은 브로민, 염소, 플루오린, 메틸, 디플루오로메틸, 트리플루오로메틸, 메톡시, 디플루오로메톡시 또는 트리플루오로메톡시이고, R7은 브로민, 염소, 플루오린, 시아노, 니트로, 히드록실, 메틸, 디플루오로메틸, 트리플루오로메틸, 메톡시, 에톡시, 디플루오로메톡시, 트리플루오로메톡시, 에티닐, 3,3,3-트리플루오로프로프-1-인-1-일 또는 시클로프로필이다.
    本发明涉及下式I的取代的氧吡啶衍生物、其制备方法及其在制备治疗和/或预防疾病,特别是心血管疾病,优选血栓性或血栓栓塞性疾病和水肿,以及眼科疾病的药物中的用途。<方案 I>在上式中,R1 是下式的基团,其中 * 是氧吡啶环的连接位点,R6 是溴、氯、氟、甲基、二氟甲基、三氟甲基、甲氧基、二氟甲氧基或三氟甲氧基、R7 是溴、氯、氟、氰基、硝基、羟基、甲基、二氟甲基、三氟甲基、甲氧基、乙氧基、二氟甲氧基、三氟甲氧基、乙炔基、3,3,3-三氟丙-1-炔-1-基或环丙基。
  • SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE
    申请人:PETRUKHIN Konstantin
    公开号:US20150315197A1
    公开(公告)日:2015-11-05
    The present invention provides a compound having the structure: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are each independently H, halogen, CF 3 or C 1 -C 4 alkyl, wherein two or more of R 1 , R 2 , R 3 , R 4 , or R 5 are other than H; R 6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R 1 is CF 3 , R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is H, R 2 is CF 3 , R 3 is H, R 4 is CF 3 , and R 5 is H, or R 1 is Cl, R 2 is H, R 3 is H, R 4 is F, and R 5 is H, or R 1 is CF 3 , R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is CF 3 , R 2 is F, R 3 is H, R 4 is H, and R 5 is H, or R 1 is Cl, R 2 is F, R 3 is H, R 4 is H, and R 5 is H, then B is other than or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有以下结构的化合物:其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基,其中R1、R2、R3、R4或R5中的两个或更多个不是H;R6为H、OH或卤素;B为取代或未取代的杂环,其中当R1为CF3、R2为H、R3为F、R4为H和R5为H,或者R1为H、R2为CF3、R3为H、R4为CF3和R5为H,或者R1为Cl、R2为H、R3为H、R4为F和R5为H,或者R1为CF3、R2为H、R3为F、R4为H和R5为H,或者R1为CF3、R2为F、R3为H、R4为H和R5为H,或者R1为Cl、R2为F、R3为H、R4为H和R5为H时,则B不是或其药学上可接受的盐。
  • Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US09434690B2
    公开(公告)日:2016-09-06
    The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    本发明涉及取代的氧代吡啶衍生物及其制备方法,以及它们用于制备药物治疗和/或预防疾病,特别是心血管疾病,优选血栓性或栓塞性疾病和水肿,以及眼科疾病的用途。
  • Substituted 4-phenylpiperidines, their preparation and use
    申请人:Petrukhin Konstantin
    公开号:US09434727B2
    公开(公告)日:2016-09-06
    The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl, wherein two or more of R1, R2, R3, R4, or R5 are other than H; R6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is H, R2 is CF3, R3 is H, R4 is CF3, and R5 is H, or R1 is Cl, R2 is H, R3 is H, R4 is F, and R5 is H, or R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is CF3, R2 is F, R3 is H, R4 is H, and R5 is H, or R1 is Cl, R2 is F, R3 is H, R4 is H, and R5 is H, then B is other than or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有以下结构的化合物:其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基,其中R1、R2、R3、R4或R5中的两个或两个以上不是H;R6为H、OH或卤素;B为取代或未取代的杂环,其中当R1为CF3,R2为H,R3为F,R4为H和R5为H,或者R1为H,R2为CF3,R3为H,R4为CF3和R5为H,或者R1为Cl,R2为H,R3为H,R4为F和R5为H,或者R1为CF3,R2为H,R3为F,R4为H和R5为H,或者R1为CF3,R2为F,R3为H,R4为H和R5为H,或者R1为Cl,R2为F,R3为H,R4为H和R5为H时,则B不是或其药学上可接受的盐。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐